PGNY — Progyny, Inc. stock price, charts and financials

QT70Progyny, Inc.

Progyny, Inc. (NASDAQ: PGNY) is a Healthcare company in the Medical - Healthcare Information Services industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
31.48
-0.05-0.16%
OverviewShort InterestFilings
PGNYQT70Progyny, Inc.·NASDAQ
31.48-0.16%
TA
Loading chart...
Screen all →
HTFL+1.94%$27.28WGS+4.48%$70.90PRVA+0.00%$23.79DOCS+1.06%$21.89WAY+4.90%$23.77CERT-4.65%$7.80TDOC+0.45%$6.71OMDA-1.61%$20.18
Snapshot
Index-P/E40.88EPS (ttm)0.77Insider Own20.00%Shs Outstand78.33MPerf Week2.34%
Market Cap2.47BForward P/E21.06EPS next Y1.49Insider Trans-0.25%Shs Float71.66MPerf Month1.78%
Enterprise Value2.27BPEG5.16EPS next Q-Inst Own-Short Float6.46%Perf Quarter66.47%
Income67.00MP/S1.91EPS this Y67.58%Inst Trans-Short Ratio3.06Perf Half Y30.03%
Sales1.29BP/B5.62EPS next Y15.85%ROA9.69%Short Interest4.63MPerf YTD22.59%
Book/sh5.60P/C10.91EPS next 5Y7.92%ROE13.34%52W High33.07 -4.81%Perf Year39.97%
Cash/sh2.89P/FCF13.22EPS past 3/5Y29.40% 6.70%ROIC13.23%52W Low16.10 95.53%Perf 3Y-22.48%
Dividend Est.-EV/EBITDA20.61Sales past 3/5Y17.88% 30.16%Gross Margin24.11%Volatility2.72% 2.99%Perf 5Y-41.00%
Dividend TTM-EV/Sales1.75EPS Y/Y TTM35.09%Oper. Margin7.46%ATR (14)0.95Perf 10Y-
Dividend Ex-Date-Quick Ratio2.13Sales Y/Y TTM10.80%Profit Margin5.23%RSI (14)59.29Recom2.30
Dividend Gr. 3/5Y-Current Ratio2.13EPS Q/Q-37.50%SMA200.01%Beta1.00Target Price34.43
Payout0.00%Debt/Eq0.05Sales Q/Q1.54%SMA509.73%Rel Volume0.53Prev Close31.53
Employees856LT Debt/Eq0.05EarningsAug 06SMA20034.21%Avg Volume1.43MPrice31.48
IPO DateOct 25, 2019Option/ShortYes / YesEPS/Sales Surpr.17.19% 0.62%Net Debt/EBITDA-0.95Volume752,736Change-0.16%
Analyst Ratings
DateActionAnalystRatingTarget
Jul-28-26DowngradeBarclaysOverweight → Equal Weight$27 → $34
Jul-24-26ReiteratedBTIGBuy$41 → $40
Jul-22-26ReiteratedLeerink PartnersOutperform$30 → $38
Jul-21-26ReiteratedCanaccord GenuityBuy$30 → $36
Jul-13-26ReiteratedKeybancOverweight$32 → $35
May-19-26UpgradeCanaccord GenuityHold → Buy$23 → $30
Mar-06-26ReiteratedJefferiesBuy$19 → $30
Mar-02-26ReiteratedTruist SecuritiesBuy$34 → $28
Jan-21-26ReiteratedJ.P. MorganNeutral$30 → $35
Jan-20-26UpgradeCitizensMarket Perform → Market Outperform
Latest News
Jul-30-26
Jul-30-2611:06AM
Progyny (PGNY) Earnings Expected to Grow: What to Know Ahead of Next Week's Releasezacks.com
Jul-29-26
Jul-29-2611:10AM
Progyny (NASDAQ:PGNY): An Affordable Growth Play With Double-Digit Earnings ExpansionChartMill
Jul-23-26
Jul-23-2603:30PM
Progyny, Inc. Announces Details for Its Second Quarter 2026 Results Reportglobenewswire.com
Jul-21-26
Jul-21-2607:39AM
Canaccord Genuity Maintains Buy on Progyny, Raises Price Target to $36Benzinga
Jul-19-26
Jul-19-2605:41AM
Progyny COO Cummings Sells 3,437 Shares for $109,000 -- Here's What That Means for Investorsfool.com
Jul-17-26
Jul-17-2610:30AM
5 Top Stocks With Relative Price Strength to Buy Right Nowzacks.com
Jul-15-26
Jul-15-2608:56AM
Top 3 Health Care Stocks That May Implode This MonthBenzinga
Jul-14-26
Jul-14-2610:15AM
Progyny, Inc. (PGNY) Hit a 52 Week High, Can the Run Continue?zacks.com
Jul-13-26
Jul-13-2608:25AM
Keybanc Maintains Overweight on Progyny, Raises Price Target to $35Benzinga
Jul-09-26
Jul-09-2601:20PM
Why Progyny (PGNY) Might be Well Poised for a Surgezacks.com
01:01PM
Are You Looking for a Top Momentum Pick? Why Progyny (PGNY) is a Great Choicezacks.com
01:01PM
What Makes Progyny (PGNY) a New Strong Buy Stockzacks.com
Jun-26-26
Jun-26-2611:20AM
Progyny Inc (NASDAQ:PGNY) Offers Affordable Growth With Strong FundamentalsChartMill
Jun-22-26
Jun-22-2601:05PM
Truist Securities Maintains Buy on Progyny, Raises Price Target to $33Benzinga
Company

Progyny, Inc. functions as a benefits management corporation, dedicated to providing specialized solutions for fertility and broader family-building initiatives to employers throughout the United States. Its core fertility offering is characterized by a distinctive benefits plan architecture, paired with personalized, white-glove member support services and access to a meticulously chosen network of top-tier fertility specialists. Additionally, the company presents Progyny Rx, an all-encompassing pharmacy benefits solution that ensures its members can readily acquire the essential medications for their treatments. Moreover, Progyny facilitates employer-sponsored reimbursement programs to support surrogacy and adoption journeys. The company, which was established in 2008 and has its main offices in New York City, previously operated as Auxogyn, Inc. before adopting the Progyny, Inc. moniker in 2015.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue1,2931,2891,1671,089787501345230105
Cost of Goods Sold Incl. D&A98298491485062038827518486
Gross Profit312304253239167112704619
Selling, General and Administrative Excl. Other21621918617714480623623
Research and Development
000000000
Other Operating Expense
000000000
Operating Income968567622332810-3
Interest Expense
000000000
Unusual Expense
—————————
Non-Operating Income (Expense)1010169100-18-3
Net Income Before Taxes10695837124329-9-7
Income Taxes3837299-6-33-380-2
Consolidated Net Income67595462306646-91
Net Income From Continuing Operations67595462306646-9-5
Net Income67595462306646-91
EPS (Recurring)0.810.680.590.650.330.740.54-0.100.01
EPS (Basic, Before Extraordinaries)0.810.680.590.650.330.740.54-0.100.01
EPS (Diluted)0.770.650.570.620.300.660.47-0.100.01
EBITDA110100867326341012-2
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio40.8839.5130.2659.97103.8376.2990.19——
Price To Sales Ratio1.971.691.353.243.648.9410.5710.03—
Gross Margin24.1323.5821.6821.9521.2222.3620.2920.0018.10
Operating Margin7.426.595.745.692.926.392.324.35-2.86
Net Margin5.184.584.635.693.8113.1713.33-3.910.95
Shares Outstanding818591959289868482
Market Capitalization2,5502,1831,5703,5322,8664,4813,6462,306—
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$34.77$29.55$24.33$19.11$13.89● Close Price0.00M0.48M0.97M1.45M1.93MUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Cummings Melissa BChief Operating OfficerJul 14 '26Sale31.602,24470,91069,934Jul 16
Swartz AllisonEVP, GCJun 04 '26Sale25.0859915,02382,378Jun 05
Livingston Mark S.CHIEF FINANCIAL OFFICERJun 04 '26Sale25.502,51764,18474,688Jun 05
Swartz AllisonEVP, GCJun 03 '26Sale25.021,19929,99983,316Jun 05
Swartz AllisonEVP, GCMay 28 '26Sale25.462,39861,05385,191Jun 01
GORDON KEVIN KDirectorMay 27 '26Sale24.995,500137,4459,318May 29
Livingston Mark S.CHIEF FINANCIAL OFFICERMay 20 '26Sale25.508,275211,01379,063May 21
Cummings Melissa BChief Operating OfficerMay 19 '26Sale25.009,578239,45073,371May 21
Swartz AllisonEVP, GCMar 04 '26Sale17.5459910,50688,941Mar 06
Swartz AllisonEVP, GCMar 03 '26Sale17.404,65781,03089,879Mar 04
Swartz AllisonEVP, GCMar 02 '26Sale17.272,19937,97797,378Mar 04
Livingston Mark S.CHIEF FINANCIAL OFFICERDec 11 '25Sale25.5045911,70546,983Dec 15
Swartz AllisonEVP, GCDec 04 '25Sale24.5953013,03372,719Dec 08
Livingston Mark S.CHIEF FINANCIAL OFFICERDec 02 '25Sale25.502135,43247,921Dec 04
Swartz AllisonEVP, GCNov 28 '25Sale26.872,39864,43473,657Dec 02
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.